Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Nature Reviews. Cancer

• Publication date

  2016-01-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrc.2015.17PMID 26822577
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Death

  2018cited by this paper
• Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

  2016cited by this paper
• Antagonism between MCL-1 and PUMA governs stem/progenitor cell survival during hematopoietic recovery from stress.

  2015cited by this paper
• The BCL-2 protein family, BH3-mimetics and cancer therapy

  2015cited by this paper
• Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

  2015cited by this paper
• Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

  2015cited by this paper
• BH3‐only proteins: a 20‐year stock‐take

  2015cited by this paper
• Cell Death

  2014cited by this paper
• Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53

  2014cited by this paper
• Many players in BCL-2 family affairs.

  2014cited by this paper
• MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice.

  2014cited by this paper
• Evaluation and critical assessment of putative MCL-1 inhibitors

  2013cited by this paper
• Mechanisms of action of Bcl-2 family proteins.

  2013cited by this paper
• Mcl-1 is essential for the survival of plasma cells

  2013cited by this paper
• Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease

  2013cited by this paper
• MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R

  2013cited by this paper
• Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

  2013cited by this paper
• ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.

  2013cited by this paper
• ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

  2013cited by this paper
• Structural biology of the Bcl-2 family and its mimicry by viral proteins

  2013cited by this paper
• Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure.

  2013cited by this paper
• Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia.

  2013cited by this paper
• Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer.

  2013cited by this paper
• Structure-guided design of a selective BCL-X(L) inhibitor.

  2013cited by this paper
• Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction.

  2013cited by this paper
• Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis.

  2013cited by this paper
• Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia.

  2012cited by this paper
• BCL-2 family member BOK is widely expressed but its loss has only minimal impact in mice

  2012cited by this paper
• Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.

  2012cited by this paper
• Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

  2012cited by this paper
• Shedding light on apoptosis at subcellular membranes.

  2012cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

  2012cited by this paper
• Targeting the B-cell lymphoma/leukemia 2 family in cancer.

  2012cited by this paper
• Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

  2011cited by this paper
• Prognostic significance of Bcl-xL gene expression in human colorectal cancer.

  2011cited by this paper
• ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2high/Mcl-1low Profile and Synergizes with Other Antineoplastic Agents

  2011cited by this paper
• miR-193b Regulates Mcl-1 in Melanoma.

  2011cited by this paper
• Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737

  2011cited by this paper
• The landscape of somatic copy-number alteration across human cancers

  2010cited by this paper
• The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

  2010cited by this paper
• Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim.

  2010cited by this paper
• Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma.

  2010cited by this paper
• Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.

  2010cited by this paper
• Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia.

  2010cited by this paper
• The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.

  2010cited by this paper
• Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

  2010cited by this paper
• Mcl-1 Is Essential for Germinal Center Formation and B Cell Memory

  2010cited by this paper
• Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

  2009cited by this paper
• Cell death.

  2009cited by this paper
• XIAP discriminates between type I and type II FAS-induced apoptosis

  2009cited by this paper
• Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis

  2009cited by this paper
• Different forms of cell death induced by putative BCL2 inhibitors

  2009cited by this paper
• Bcl-2 family members: dual regulators of apoptosis and autophagy.

  2008cited by this paper
• Bcl-2 family members: Dual regulators of apoptosis and autophagy

  2008cited by this paper
• BCL-2 family antagonists for cancer therapy

  2008cited by this paper
• ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

  2008cited by this paper
• In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute

  2008cited by this paper
• Mcl-1 Is a Key Regulator of Apoptosis during CNS Development and after DNA Damage

  2008cited by this paper
• Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).

  2008cited by this paper
• Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

  2008cited by this paper
• How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?

  2008cited by this paper
• BAX Activation is Initiated at a Novel Interaction Site

  2008cited by this paper
• Selection against PUMA Gene Expression in Myc-Driven B-Cell Lymphomagenesis

  2008cited by this paper
• Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.

  2008cited by this paper
• Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas

  2007cited by this paper
• Bax and the mitochondrial permeability transition cooperate in the release of cytochrome c during endoplasmic reticulum-stress-induced apoptosis

  2007cited by this paper
• Programmed anuclear cell death delimits platelet life span.

  2007cited by this paper
• ER stress triggers apoptosis by activating BH3-only protein Bim.

  2007cited by this paper
• Bcl-2 family proteins are essential for platelet survival

  2007cited by this paper
• BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.

  2007cited by this paper
• NIX is required for programmed mitochondrial clearance during reticulocyte maturation

  2007cited by this paper
• Embedded together: The life and death consequences of interaction of the Bcl-2 family with membranes

  2007cited by this paper
• Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak

  2007cited by this paper
• Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains

  2007cited by this paper
• Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics

  2007cited by this paper
• BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

  2007cited by this paper
• Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak.

  2006cited by this paper
• The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

  2006cited by this paper
• Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic

  2006cited by this paper
• Gossypol induces Bax/Bak‐independent activation of apoptosis and cytochrome c release via a conformational change in Bcl‐2

  2006cited by this paper
• Competing Interests: The authors

  2006cited by this paper
• Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction

  2006cited by this paper
• miR-15 and miR-16 induce apoptosis by targeting BCL2.

  2005cited by this paper
• Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.

  2005cited by this paper
• MCLI , a gene expressed in programmed myeloid cell differentiation , has sequence similarity to BCL 2

  2005cited by this paper
• BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly.

  2005cited by this paper
• Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM

  2005cited by this paper
• Obligate Role of Anti-Apoptotic MCL-1 in the Survival of Hematopoietic Stem Cells

  2005cited by this paper
• An inhibitor of Bcl-2 family proteins induces regression of solid tumours

  2005cited by this paper
• BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo.

  2005cited by this paper
• Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die

  2004cited by this paper
• Roles of Bim in Apoptosis of Normal and Bcr-Abl-Expressing Hematopoietic Progenitors

  2004cited by this paper
• Bim is a suppressor of Myc-induced mouse B cell leukemia.

  2004cited by this paper
• The Pathophysiology of Mitochondrial Cell Death

  2004cited by this paper
• p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa

  2003cited by this paper
• Puma is an essential mediator of p53-dependent and -independent apoptotic pathways.

  2003cited by this paper
• Integral role of Noxa in p53-mediated apoptotic response.

  2003cited by this paper
• Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1

  2003cited by this paper
• The structure of a Bcl-xL/Bim fragment complex: implications for Bim function.

  2003cited by this paper

• Programmed cell death of keratinocytes: an active driver in psoriasis

  2026cites this paper
• Mechanisms of tumor cell evasion from NK cell-mediated killing and advances in NK cell-based cancer immunotherapy.

  2026cites this paper
• Dual-Targeting Bcl-2-Mediated apoptosis and synergistic Pathways: Combinatorial strategies to overcome therapeutic resistance in cancer.

  2026cites this paper
• Combined Nudged Elastic Band and Markov State Models Uncover Distinct BAX Activation Pathways by Bim Peptide and a Small Molecule.

  2026cites this paper
• Targeted Nanoencapsulation of Tunicamycin Reduces Toxicity While Improving its Therapeutic Effectiveness in Pancreatic Cancer Cells

  2025cites this paper
• Reln-Dab1 pathway mitigates retinal ganglion cell apoptosis in retinal ischemia-reperfusion injury

  2025cites this paper
• Regulation of elevated expression of Mcl-1 in hepatocellular carcinoma – a review

  2025cites this paper
• Non-apoptotic caspase-8 is critical for orchestrating exaggerated inflammation during severe SARS-CoV-2 infection

  2025cites this paper
• Dynamical analysis of a model of BCL-2-dependent cellular decision making

  2025influential citation
• Treatment of NSCLC after chemoimmunotherapy — are we making headway?

  2025cites this paper
• Fluorinated albumin nanocages dually target CAFs and tumor cells to potentiate bladder cancer chemoimmunotherapy.

  2025cites this paper
• The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast Cancer

  2025cites this paper
• Extracellular vesicle-associated lncRNA LYPLAL1-DT mediates endothelial-cancer cell communication, promoting small cell lung cancer progression

  2025cites this paper
• Common and rare variant analyses reveal genetic factors underlying idiopathic pulmonary fibrosis and its shared aetiology with severe COVID-19

  2025cites this paper
• Integrative genomic analyses combined with molecular dynamics simulations reveal the impact of deleterious mutations of Bcl-2 gene on the apoptotic machinery and implications in carcinogenesis

  2025cites this paper
• Deep transfer learning approach for automated cell death classification reveals novel ferroptosis-inducing agents in subsets of B-ALL

  2025influential citation
• AT101 Suppresses Gastrointestinal Stromal Tumor Growth and Promotes Apoptosis via YAP/TAZ–CCND1 and FBXW7–MCL1 Axes

  2025cites this paper
• Exploring the Genetic Orchestra of Cancer: The Interplay Between Oncogenes and Tumor-Suppressor Genes

  2025cites this paper
• Medicago sativa Extracts Enhance the Anticancer Efficacy of GEM in PANC-1 Cells through Apoptosis Induction and BAX/BCL-2/CASP3 Expression Modulation

  2025cites this paper
• The Role of the BCL2 Family in Targeted Anticancer Response as Apoptotic Mediators

  2025cites this paper
• Targeted nanoencapsulation of tunicamycin reduces toxicity while improving its therapeutic effectiveness in pancreatic cancer cells

  2025cites this paper
• The Role of Insulin Resistance in Cancer

  2025cites this paper
• Lysosomal Cathepsin S Escape Facilitates Near Infrared Light‐Triggered Pyroptosis Via an Antibody‐Indocyanine Green Conjugate

  2025cites this paper
• TH-302 (evofosfamide) monotherapy exerts anticancer activity in Ewing's sarcoma cells under hypoxia

  2025cites this paper
• Targeting MCM10 disrupts cancer stemness and counteracts sorafenib resistance in hepatocellular carcinoma

  2025cites this paper
• Discovery of Dual BCL-xL/BCL-w Degraders by Exploiting the Bis(sulfonyl)benzene Ring of ABT-263 as a Linkage Vector.

  2025cites this paper
• Hypericin Photodynamic Therapy Induces Cytotoxicity and Modulates Cytokine Secretion in MCF-7 Breast Cancer Cells

  2025cites this paper
• Distinct Flower signaling domains orchestrate cellular fitness via secreted vesicles in Aβ-induced neurodegeneration

  2025cites this paper
• Betulinic acid and apoptosis-involved pathways: Unveiling its bidirectional regulatory role.

  2025cites this paper
• Multi-omics advances in understanding cancer drug resistance

  2025cites this paper
• Evaluation the Kidney Protection Effect of Rosuvastatin against I\R injury in male rats. Assessment the Effect of Rosuvastatin on mTOR gene

  2025cites this paper
• Modulation Renal Expression of mTOR Gene via Calcitriol on RIRI in Rats

  2025cites this paper
• From Chemotherapy to Targeted Therapy: Unraveling Resistance in Acute Myeloid Leukemia Through Genetic and Non-Genetic Insights

  2025cites this paper
• The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy

  2025cites this paper
• The association between NADPH oxidase (NOX) polymorphisms with immunohistochemistry and survival in diffuse large B cell lymphoma patients

  2025cites this paper
• Screening of necroptosis-related genes and evaluating the prognostic capacity, clinical value, and the effect of their copy number variations in acute myeloid leukemia

  2025cites this paper
• Homoharringtonine: mechanisms, clinical applications and research progress

  2025cites this paper
• Understanding of Benzophenone UV Absorber-Induced Damage and Apoptosis in Human Hepatoma Cells

  2025cites this paper
• TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas.

  2025cites this paper
• A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Minimizes Ex Vivo Reservoirs from Patients

  2025cites this paper
• Novel In Vitro Selection of Trans-Acting BCL-2 mRNA-Cleaving Deoxyribozymes for Cancer Therapy

  2025cites this paper
• Novel Nitrogen Heterocycle–Hydroxamic Acid Conjugates Demonstrating Potent Anti-Acute Lymphoblastic Leukemia Activity: Induction of Endogenous Apoptosis and G0/G1 Arrest via Regulation of Histone H3 Acetylation and AKT Phosphorylation in Jurkat Cells

  2025cites this paper
• Nanotherapeutics-induced pyroptosis for targeted cancer therapy: mechanistic insights and translational prospects.

  2025cites this paper
• The multiplex crosstalk between non-coding RNAs, programmed cell death and related mechanisms: a dynamic duo in hematological malignancies

  2025cites this paper
• Phytochemicals Daturilinol and Withametelin B identified as novel Bcl2 inhibitors via virtual screening and molecular simulations

  2025cites this paper
• Bio-efficacy of Hedyotis sithiravaraiensis Callus Extract: A Stepwise Evaluation Through Phytochemical Profiling, Antioxidant Activity, Molecular Docking, and Cytotoxic Study

  2025cites this paper
• Albumin nanocomplex of BCL-2/xL inhibitor reduced platelet toxicity and improved anticancer efficacy in myeloproliferative neoplasm and lymphoma.

  2025cites this paper
• Depletion of SASP senescent cardiomyocytes with senolytic drugs confers therapeutic effects in doxorubicin‐related cardiotoxicity

  2024cites this paper
• CXCR4-Mediated Codelivery of FLT3 and BCL-2 Inhibitors for Enhanced Targeted Combination Therapy of FLT3-ITD Acute Myeloid Leukemia.

  2024cites this paper
• Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies

  2024cites this paper
• Tumor biomarkers for diagnosis, prognosis and targeted therapy

  2024cites this paper
• Advancements in precision nanomedicine design targeting the anoikis-platelet interface of circulating tumor cells

  2024cites this paper
• The role of tumor-associated macrophages in the radioresistance of esophageal cancer cells via regulation of the VEGF-mediated angiogenic pathway

  2024cites this paper
• Mitochondrial bioenergetics as a cell fate rheostat for responsive to Bcl-2 drugs: New cues for cancer chemotherapy.

  2024cites this paper
• Topical BCl‐2 inhibitor (ABT‐737) attenuates skin photoaging in mice

  2024cites this paper
• Therapeutic Stapled Peptides: Efficacy and Molecular Targets.

  2024cites this paper
• Unlocking the Therapeutic Potential of BCL-2 Associated Protein Family: Exploring BCL-2 Inhibitors in Cancer Therapy

  2024cites this paper
• Directly targeting BAX for drug discovery: Therapeutic opportunities and challenges

  2024cites this paper
• Glycyrrhetinic acid inhibits non-small cell lung cancer via promotion of Prdx6- and caspase-3-mediated mitochondrial apoptosis.

  2024cites this paper
• Overview of BH3 mimetics in ovarian cancer.

  2024cites this paper
• Review of the impact of fragment-based drug design on PROTAC degrader discovery

  2024cites this paper
• Recent advancement in pyrrolidine moiety for the management of cancer: A review

  2024cites this paper
• Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy

  2024cites this paper
• Regulated Cell Death in Endometriosis

  2024cites this paper
• Gasdermin and MLKL necrotic cell death effectors: Signaling and diseases.

  2024cites this paper
• Cyclodextrin-based delivery systems for chemical and genetic drugs: Current status and future.

  2024cites this paper
• Bio-mimetic strategies to re-activate apoptotic cell death for cancer treatments

  2024cites this paper
• Mesoporous polydopamine composite nanoparticles for multimodal therapy based on disrupting the redox homeostasis within tumor cells.

  2024cites this paper
• Targeting Bcl-2 with Indole Scaffolds: Emerging Drug Design Strategies for Cancer Treatment.

  2024cites this paper
• Characterizing and Targeting of BCL‐2 Family Members in Nasopharyngeal Carcinoma

  2024cites this paper
• Anticancer effects of washed-dehydrated solar salt doenjang and its metabolites

  2024cites this paper
• Preliminary study of the mechanism of isolinderalactone inhibiting the malignant behavior of bladder cancer

  2024cites this paper
• Don't fear the reaper: The role of regulated cell death in tumorigenesis and BH3-mimetics for cancer therapy.

  2024cites this paper
• A smart-responsive Y-shaped DNA scaffold drug conjugate achieving precise and synergetic tumor chemo-gene therapy via promoting tumor apoptosis and activating the anti-tumor immunity

  2024cites this paper
• Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway

  2024cites this paper
• 2-hydroxy-3-methyl anthraquinone promotes apoptosis and inhibits invasion of human hepatocellular carcinoma cells by targeting nicotinamide adenine dinucleotide-dependent protein deacetylase sirtuin-1/cellular tumor antigen p53 signaling pathway.

  2024cites this paper
• Chromosome instability functions as a potential therapeutic reference by enhancing chemosensitivity to BCL-XL inhibitors in colorectal carcinoma

  2024cites this paper
• The Role of Bcl-2 Family Proteins and Sorafenib Resistance in Hepatocellular Carcinoma

  2024cites this paper
• Effects of 630 nm laser on apoptosis, metastasis, invasion and epithelial-to-mesenchymal transition of human lung squamous cell carcinoma H520 cells mediated by hematoporphyrin derivatives

  2024cites this paper
• Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies

  2024cites this paper
• LINC complex protein nesprin-2 has pro-apoptotic activity via Bcl-2 family proteins

  2024cites this paper
• Nucleolar protein TAAP1/C22orf46 confers pro-survival signaling in non-small cell lung cancer

  2024influential citation
• Nano delivery of juglone causes cell cycle arrest and apoptosis for hepatocellular carcinoma therapy

  2024cites this paper
• Emerging biomarkers and potential therapeutics of the BCL-2 protein family: the apoptotic and anti-apoptotic context

  2024influential citation
• Cerium oxide nanoparticles: Chemical properties, biological effects and potential therapeutic opportunities (Review)

  2024cites this paper
• Development of Potent Mcl-1 Inhibitors: Structural Investigations on Macrocycles Originating from a DNA-Encoded Chemical Library Screen.

  2024cites this paper
• The role of RNA viruses in human cancers

  2024cites this paper
• Common and rare variant analyses reveal novel genetic factors underlying Idiopathic Pulmonary Fibrosis and shared aetiology with COVID-19

  2024cites this paper
• Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies.

  2024cites this paper
• High-grade B-cell lymphoma with a quadruple-hit genetic profile including concurrent MYC, BCL2, BCL6, and CCND1 gene rearrangements.

  2024cites this paper
• Small molecules targeting mitochondria as an innovative approach to cancer therapy.

  2024cites this paper
• Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center

  2024cites this paper
• Cardiolipin oxidized by ROS from complex II acts as a target of gasdermin D to drive mitochondrial pore and heart dysfunction in endotoxemia.

  2024cites this paper
• Sperm freezing damage: the role of regulated cell death

  2024cites this paper
• CDK12 is a promising therapeutic target for the transcription cycle and DNA damage response in metastatic osteosarcoma.

  2024cites this paper
• CAR-T cell combination therapies in hematologic malignancies

  2024cites this paper
• Efficient Light-Based Bioprinting via Rutin Nanoparticle Photoinhibitor for Advanced Biomedical Applications.

  2024cites this paper
• An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity

  2024cites this paper
• Design, synthesis, and evaluation of BCL-2 targeting PROTACs.

  2024cites this paper
• Carbazole Derivatives Binding to Bcl-2 Promoter Sequence G-quadruplex

  2024cites this paper